From these pathological observations, it is suggested that an undifferentiated tumor component with a SMARCA4 deficiency arose, in part, from a background of preexisting urothelial carcinoma, resulting in early retroperitoneal recurrence after TUR‐BT. Here, SMARCA4 is linked to urothelial carcinoma.